APLLTD.NS Stock Analysis
AP
Avoid
Based on Eyestock quantitative analysis, APLLTD.NS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Market cap $B
1.328
Dividend yield
1.92 %
Shares outstanding
196.56 B
Alembic Pharmaceuticals Ltd. is a research and development pharmaceutical company, which engages in the research, development, manufacture, and market of generic and branded pharmaceutical products. The company is headquartered in Vadodara, Gujarat and currently employs 14,593 full-time employees. The company went IPO on 2011-09-17. The firm is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients (API). The company delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopaedic and Gynaecology. Products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. The company has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its India Formulations. Its subsidiaries include Alembic Pharmaceuticals Inc., Alembic Global Holding SA and others.